Skip to main content
Top
Published in: International Urology and Nephrology 4/2009

01-12-2009 | Nephrology - Original Paper

Loss via peritoneal fluid as a factor for low 25(OH)D3 level in peritoneal dialysis patients

Authors: Garip Sahin, Ismail Kirli, Basar Sirmagul, Ertugrul Colak, Ahmet Ugur Yalcin

Published in: International Urology and Nephrology | Issue 4/2009

Login to get access

Abstract

Background/aims

In patients with end-stage renal disease (ESRD), the 25-hydroxyvitamin D3 (25(OH)D3) level is known to be lower compared to that of the normal population. In the present study, we evaluated the influences of dialysis methods on the serum 25(OH)D3 level in patients with ESRD who are treated with hemodialysis and peritoneal dialysis.

Methods

Thirty-nine peritoneal dialysis (PD), 49 hemodialysis (HD) patients, and 33 healthy controls were included in the present study. The mean HD period was 30.38 ± 21.81 months and the mean PD period was 26.35 ± 24.04 months. Serum samples from the HD and PD patients and healthy controls were examined in terms of 25(OH)D3, intact parathyroid hormone (iPTH), and other biochemical laboratory tests. Additionally, the 25(OH)D3 level in the peritoneal fluid was analyzed in the PD group.

Results

The mean 25(OH)D3 levels in the control, HD, and PD groups were 26.63 ± 10.89, 21.65 ± 12.38, and 13.46 ± 9.41 nmol/l, respectively (P < 0.001). The mean peritoneal fluid 25(OH)D3 level was 28.53 ± 7.66 nmol/l. Moreover, blood and PD fluid 25(OH)D3 levels were 34 compared in the PD group. The 25(OH)D3 level in dialysate was higher than that of serum in PD patients (P < 0.001).

Conclusion

The significantly lower blood levels of 25(OH)D3 in PD patients compared to those of HD patients were thought to be due to 25(OH)D3 loss via peritoneal fluid.
Literature
5.
go back to reference National Kidney Foundation (2003) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42(4 Suppl 3):7–201 National Kidney Foundation (2003) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42(4 Suppl 3):7–201
6.
go back to reference Saha H (1994) Calcium and vitamin D homeostasis in patients with heavy proteinuria. Clin Nephrol 41:290–296PubMed Saha H (1994) Calcium and vitamin D homeostasis in patients with heavy proteinuria. Clin Nephrol 41:290–296PubMed
7.
10.
go back to reference González EA, Sachdeva A, Oliver DA, Martin KJ (2004) Vitamin D insufficiency and deficiency in chronic kidney disease. a single center observational study. Am J Nephrol 24(5):503–510. doi:10.1159/000081023 CrossRefPubMed González EA, Sachdeva A, Oliver DA, Martin KJ (2004) Vitamin D insufficiency and deficiency in chronic kidney disease. a single center observational study. Am J Nephrol 24(5):503–510. doi:10.​1159/​000081023 CrossRefPubMed
11.
go back to reference Shah N, Bernardini J, Piraino B (2005) Prevalence and correction of 25(OH) vitamin D deficiency in peritoneal dialysis patients. Perit Dial Int 25(4):362–366PubMed Shah N, Bernardini J, Piraino B (2005) Prevalence and correction of 25(OH) vitamin D deficiency in peritoneal dialysis patients. Perit Dial Int 25(4):362–366PubMed
12.
go back to reference Taskapan H, Ersoy FF, Passadakis PS, Tam P, Memmos DE, Katopodis KP, Ozener C, Akcicek F, Camsari T, Ates K, Ataman R, Vlachojannis JG, Dombros NA, Utas C, Akpolat T, Bozfakioglu S, Wu G, Karayaylali I, Arinsoy T, Stathakis CP, Yavuz M, Tsakiris DJ, Dimitriades AD, Yilmaz ME, Gültekin M, Oreopoulos DG (2006) Severe vitamin D deficiency in chronic renal failure patients on peritoneal dialysis. Clin Nephrol 66(4):247–255PubMed Taskapan H, Ersoy FF, Passadakis PS, Tam P, Memmos DE, Katopodis KP, Ozener C, Akcicek F, Camsari T, Ates K, Ataman R, Vlachojannis JG, Dombros NA, Utas C, Akpolat T, Bozfakioglu S, Wu G, Karayaylali I, Arinsoy T, Stathakis CP, Yavuz M, Tsakiris DJ, Dimitriades AD, Yilmaz ME, Gültekin M, Oreopoulos DG (2006) Severe vitamin D deficiency in chronic renal failure patients on peritoneal dialysis. Clin Nephrol 66(4):247–255PubMed
13.
go back to reference Gokal R, Ramos JM, Ellis HA, Parkinson I, Sweetman V, Dewar J, Ward MK, Kerr DN (1983) Histological renal osteodystrophy, and 25 hydroxycholecalciferol and aluminum levels in patients on continuous ambulatory peritoneal dialysis. Kidney Int 23(1):15–21. doi:10.1038/ki.1983.4 CrossRefPubMed Gokal R, Ramos JM, Ellis HA, Parkinson I, Sweetman V, Dewar J, Ward MK, Kerr DN (1983) Histological renal osteodystrophy, and 25 hydroxycholecalciferol and aluminum levels in patients on continuous ambulatory peritoneal dialysis. Kidney Int 23(1):15–21. doi:10.​1038/​ki.​1983.​4 CrossRefPubMed
14.
go back to reference Aloni Y, Shany S, Chaimovitz C (1983) Losses of 25-hydroxyvitamin D in peritoneal fluid: possible mechanism for bone disease in uremic patients treated with chronic ambulatory peritoneal dialysis. Miner Electrolyte Metab 9(2):82–86PubMed Aloni Y, Shany S, Chaimovitz C (1983) Losses of 25-hydroxyvitamin D in peritoneal fluid: possible mechanism for bone disease in uremic patients treated with chronic ambulatory peritoneal dialysis. Miner Electrolyte Metab 9(2):82–86PubMed
15.
go back to reference Zucchelli P, Catizone L, Casanova S, Fusaroli M, Fabbri L, Ferrari G (1984) Renal osteodystrophy in CAPD patients. Miner Electrolyte Metab 10(5):326–332PubMed Zucchelli P, Catizone L, Casanova S, Fusaroli M, Fabbri L, Ferrari G (1984) Renal osteodystrophy in CAPD patients. Miner Electrolyte Metab 10(5):326–332PubMed
16.
go back to reference Hart GR, Furniss JL, Laurie D, Durham SK (2006) Measurement of vitamin D status: background, clinical use, and methodologies. Clin Lab (Zaragoza) 52(7–8):335–343 Hart GR, Furniss JL, Laurie D, Durham SK (2006) Measurement of vitamin D status: background, clinical use, and methodologies. Clin Lab (Zaragoza) 52(7–8):335–343
17.
go back to reference Hyppönen E, Turner S, Cumberland P, Power C, Gibb I (2007) Serum 25-hydroxyvitamin D measurement in a large population survey with statistical harmonization of assay variation to an international standard. J Clin Endocrinol Metab 92(12):4615–4622. doi:10.1210/jc.2007-1279 CrossRefPubMed Hyppönen E, Turner S, Cumberland P, Power C, Gibb I (2007) Serum 25-hydroxyvitamin D measurement in a large population survey with statistical harmonization of assay variation to an international standard. J Clin Endocrinol Metab 92(12):4615–4622. doi:10.​1210/​jc.​2007-1279 CrossRefPubMed
20.
go back to reference Ghazali A, Fardellone P, Pruna A, Atik A, Achard JM, Oprisiu R, Brazier M, Remond A, Morinière P, Garabedian M, Eastwood J, Fournier A (1999) Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser’s zones independent of calcitriol? Kidney Int 55(6):2169–2177. doi:10.1046/j.1523-1755.1999.00480.x CrossRefPubMed Ghazali A, Fardellone P, Pruna A, Atik A, Achard JM, Oprisiu R, Brazier M, Remond A, Morinière P, Garabedian M, Eastwood J, Fournier A (1999) Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser’s zones independent of calcitriol? Kidney Int 55(6):2169–2177. doi:10.​1046/​j.​1523-1755.​1999.​00480.​x CrossRefPubMed
21.
go back to reference Mucsi I, Almási C, Deák G, Marton A, Ambrus C, Berta K, Lakatos P, Szabó A, Horváth C (2005) Serum 25(OH)-vitamin D levels and bone metabolism in patients on maintenance hemodialysis. Clin Nephrol 64(4):288–294PubMed Mucsi I, Almási C, Deák G, Marton A, Ambrus C, Berta K, Lakatos P, Szabó A, Horváth C (2005) Serum 25(OH)-vitamin D levels and bone metabolism in patients on maintenance hemodialysis. Clin Nephrol 64(4):288–294PubMed
22.
23.
go back to reference Kurtz SB, McCarthy JT, Kumar R (1981) Hypercalcemia in continuous ambulatory peritoneal dialysis (CAPD) patients: observations on parameters of calcium metabolism. In: Gahl GM, Kessel M, Nolph KD (eds) Advances in peritoneal dialysis. Excerpta Medica, Amsterdam, pp 467–472 Kurtz SB, McCarthy JT, Kumar R (1981) Hypercalcemia in continuous ambulatory peritoneal dialysis (CAPD) patients: observations on parameters of calcium metabolism. In: Gahl GM, Kessel M, Nolph KD (eds) Advances in peritoneal dialysis. Excerpta Medica, Amsterdam, pp 467–472
24.
go back to reference Cassidy MJ, Owen JP, Ellis HA, Dewar J, Robinson CJ, Wilkinson R, Ward MK, Kerr DN (1985) Renal osteodystrophy and metastatic calcification in long-term continuous ambulatory peritoneal dialysis. Q J Med 54(213):29–48PubMed Cassidy MJ, Owen JP, Ellis HA, Dewar J, Robinson CJ, Wilkinson R, Ward MK, Kerr DN (1985) Renal osteodystrophy and metastatic calcification in long-term continuous ambulatory peritoneal dialysis. Q J Med 54(213):29–48PubMed
28.
go back to reference Gelev S, Spasovski GB, Dzikova S, Trajkovski Z, Damjanovski G, Amitov V, Sikole A (2008) Vascular calcification and atherosclerosis in hemodialysis patients: what can we learn from the routine clinical practice? Int Urol Nephrol 40:763–770. doi:10.1007/s11255-008-9379-y CrossRefPubMed Gelev S, Spasovski GB, Dzikova S, Trajkovski Z, Damjanovski G, Amitov V, Sikole A (2008) Vascular calcification and atherosclerosis in hemodialysis patients: what can we learn from the routine clinical practice? Int Urol Nephrol 40:763–770. doi:10.​1007/​s11255-008-9379-y CrossRefPubMed
Metadata
Title
Loss via peritoneal fluid as a factor for low 25(OH)D3 level in peritoneal dialysis patients
Authors
Garip Sahin
Ismail Kirli
Basar Sirmagul
Ertugrul Colak
Ahmet Ugur Yalcin
Publication date
01-12-2009
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 4/2009
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-009-9561-x

Other articles of this Issue 4/2009

International Urology and Nephrology 4/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.